U-Blot® Research Grade Talacotuzumab
Ucallm.jpg
$9,999.00
Product details
Background：Talacotuzumab (TAL, JNJ-56022473) is an IgG1 monoclonal antibody targeting CD123 preferentially via antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells and has been shown to induce potent in vitro ADCC against IL3RA-expressing AML blasts/LSC and to reduce leukemic cell growth in murine xenograft models of human AML. In addition, the antibody inhibits signaling by IL-3, the main ligand of CD123, to reduce the proliferation of leukemic progenitor cells.
• CD123 and its potential clinical application in leukemias., PMID:25445480
• Interleukin-3 receptor in acute leukemia., PMID:14671644
• IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway., PMID:29238040
• The role of interleukin-3 in classical Hodgkin’s disease., PMID:15621820
• IL-3 Decreases Cartilage Degeneration by Downregulating Matrix Metalloproteinases and Reduces Joint Destruction in Osteoarthritic Mice., PMID:27183574
• New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells., PMID:17667524
• Receptor cross-linking on human plasmacytoid dendritic cells leads to the regulation of IFN-alpha production., PMID:17056507
• AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells., PMID:25879549
• Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice., PMID:16882709
• SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia., PMID:24942980
Specifications
| Target | CD123 |
| Reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| MW(Calculated) | |
| MW(Observed) | |
| Host Species | Humanized |
| Isotype | IgG1-kappa |
| Conjugate/Modification | |
| Modification | |
| Recommended Dilution Ratio | |
| Composition | 0.01M PBS, pH 7.4. |
| Purification Process | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Storage Condition | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Concentration | |
| Clonality | Monoclonal |
| Clone Number | |
| Immunogen | Mammalian Cells |
| Gene Name | |
| Protein Name | |
| Alias | IL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA |
| Species | |
| Gene ID-1 | P26951 |
| Uniprot | |
| Species.1 | |
| Gene ID | |
| Uniprot.1 | |
| Species.2 | |
| Gene ID.1 | |
| Uniprot.2 | |
| Organism-4 | |
| Gene ID-4 | |
| SwissProt-4 | |
| Description | Background：Talacotuzumab (TAL, JNJ-56022473) is an IgG1 monoclonal antibody targeting CD123 preferentially via antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells and has been shown to induce potent in vitro ADCC against IL3RA-expressing AML blasts/LSC and to reduce leukemic cell growth in murine xenograft models of human AML. In addition, the antibody inhibits signaling by IL-3, the main ligand of CD123, to reduce the proliferation of leukemic progenitor cells.<br>• CD123 and its potential clinical application in leukemias., PMID:25445480<br />• Interleukin-3 receptor in acute leukemia., PMID:14671644<br />• IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway., PMID:29238040<br />• The role of interleukin-3 in classical Hodgkin's disease., PMID:15621820<br />• IL-3 Decreases Cartilage Degeneration by Downregulating Matrix Metalloproteinases and Reduces Joint Destruction in Osteoarthritic Mice., PMID:27183574<br />• New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells., PMID:17667524<br />• Receptor cross-linking on human plasmacytoid dendritic cells leads to the regulation of IFN-alpha production., PMID:17056507<br />• AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells., PMID:25879549<br />• Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice., PMID:16882709<br />• SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia., PMID:24942980<br /> |
| Cellular Localization | |
| Tissue Expression | |
| Signaling_pathway | |
| Research Areas | |
| Function |
Please login to post questions
Related products
